Cortexyme, Inc. (NASDAQ:CRTX - Get Free Report) shares crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.06 and traded as high as $1.74. Cortexyme shares last traded at $1.71, with a volume of 141,555 shares trading hands.
Cortexyme Price Performance
The firm has a market cap of $58.19 million, a P/E ratio of -0.65 and a beta of 1.40. The company's 50 day moving average is $1.71 and its two-hundred day moving average is $1.06.
About Cortexyme
(
Get Free Report)
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Further Reading
Before you consider Cortexyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cortexyme wasn't on the list.
While Cortexyme currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
